RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07592-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Kaylee Molin und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia. kaylee.molin@research.uwa.edu.au. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Western Australia.
Abstract (Originalsprache)
Purpose
Up to 40% of prostate cancer (PCa) patients experience biochemical recurrence (BCR) after primary treatment, but reliable tools for risk stratification in this setting are limited. This study compared Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) and PSMA PET Progression (PPP) criteria in predicting overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). As a secondary aim, PROMISE-based nomograms were assessed as tools for OS prediction.
Methods
A cohort of 154 BCR PCa patients with baseline and follow-up [ 68 Ga]Ga-PSMA-11 PET/CT was analysed. Disease progression was defined by RECIP 1.0 and three PPP variants (PPP-Volume, PPP-Mean SUV, PPP-Max SUV). Associations with OS and PSA-PFS were tested using Kaplan–Meier and Cox regression models. PROMISE-based visual and quantitative nomograms were applied to follow-up scans to predict OS. Subgroup analyses by treatment type were performed for RECIP and PPP criteria.
Results
RECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41–8.87; p < 0.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT + radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT + radiotherapy.
Conclusion
In BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification. Trial registration number ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia. kaylee.molin@research.uwa.edu.au.
- Centre for Advanced Technologies in Cancer Research (CATCR), Perth, WA, Australia. kaylee.molin@research.uwa.edu.au.
- Department of Nuclear Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia.
- Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
- Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
- Medical School, University of Western Australia, Crawley, WA, Australia.
ORCID-Profile: Kaylee Molin, Jeremy S L Ong, Roslyn J Francis, Ghulam Mubashar Hassan, Martin A Ebert, Jake Kendrick
Förderung
- University of Western Australia
Zitieren
APA
Molin, K., Ong, J. S. L., Werf, S. V., Francis, R. J., Hassan, G. M., Ebert, M. A., & Kendrick, J. (2026). RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07592-6
Vancouver
Molin K, Ong JSL, Werf SV, Francis RJ, Hassan GM, Ebert MA, et al. RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07592-6
BibTeX
@article{Molin2026,
author = {Molin, Kaylee and Ong, Jeremy S L and Werf, Steven Van Der and Francis, Roslyn J and Hassan, Ghulam Mubashar and Ebert, Martin A and Kendrick, Jake},
title = {RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07592-6}
}
EUVIMED